Novo Nordisk's Wegovy weight-loss drug sales beat forecast, …
6 days ago · Wegovy Q3 sales total $2.5 bln. Beat forecast but group sales weaker than expected. Results soothe investor worries over slowing obesity drug demand. Shares rose …
Novo Nordisk shares jump 8% after Wegovy sales beat …
Nov 6, 2024 · Novo Nordisk added that sales of Wegovy were 79% higher year-on-year in the third quarter, coming in at 17.3 billion Danish kroner. ... The news was taken as a signal that …
Novo Nordisk Dominates Obesity Market as Wegovy Sales Soar …
6 days ago · Novo Nordisk (NYSE:NVO) is stealing the spotlight in the obesity drug market as Wegovy's sales skyrocketed by 76% year-over-year to DKK 38.3 billion, crushing analysts' …
Strong Wegovy revenue growth for Novo Nordisk but shares dip
6 days ago · Novo Nordisk’s net profit of $3.94bn represents a 21% increase from Q3 2023. Net sales in the quarter jumped by the same amount, totalling $10.6bn. The company narrowed its …
Novo sees Wegovy sales rise as supply constraints ease
Nov 6, 2024 · Sales of Novo Nordisk’s obesity drug Wegovy were 81% higher in the third quarter of 2024 than the same period last year amid loosening supply constraints and broader …
News details - Novo Nordisk
Mar 8, 2024 · Wegovy® receives FDA approval for cardiovascular risk reduction in adults with known heart disease and overweight or obesity. Wegovy® (semaglutide) injection 2.4 mg is …
News Details - Novo Nordisk
Mar 8, 2024 · "We are very pleased that Wegovy ® is now approved in the US as the first therapy to help people manage their weight and reduce cardiovascular risks," said Martin Holst Lange, …
News details - Novo Nordisk
Nov 11, 2023 · Novo Nordisk has filed for a label update of Wegovy ® in the US and EU to include an indication for reducing the risk of major adverse cardiovascular events …
News Details - Novo Nordisk
Jun 4, 2021 · Wegovy™ is the first and only once-weekly glucagon-like peptide-1 (GLP-1) receptor agonist therapy approved for weight management for people living with obesity. The …
News details - Novo Nordisk
PLAINSBORO, NJ, December 23, 2022 – Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved a new indication for Wegovy ® (semaglutide) …